Drug Profile


Alternative Names: RGH 0205; TP3

Latest Information Update: 08 Nov 2006

Price : $50

At a glance

  • Originator Gedeon Richter
  • Class Antirheumatics
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; HIV infections; Rheumatic disorders

Most Recent Events

  • 08 Nov 2006 Discontinued - Phase-II for HIV infections treatment in United Kingdom (unspecified route)
  • 08 Nov 2006 Discontinued for Rheumatic disorders (unspecified route)
  • 08 Nov 2006 Discontinued - Phase-II for Cancer in Hungary (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top